MEI Pharma develops cancer therapies. Zandelisib is an oral phosphatidylinositol 3-kinase delta inhibitor for relapsed/refractory follicular lymphoma. Voruciclib is an oral cyclin-dependent kinase 9 inhibitor in Phase I trial for acute myeloid leukemia and B-cell malignancies. ME-344, a mitochondrial inhibitor, has completed Phase I clinical trial for human epidermal growth factor receptor 2 negative breast cancer.
| Indicator | Value |
|---|---|
| PER | 31.9 |
| EV/EBITDA | 18.3 |
| Price/Free Cash Flow' | 81.2 |
| ROIC | 13.5% |
| Net Debt/EBITDA | 2.0 |